Kupando GmbH Information

Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to build a pipeline in several indications, in-house or via strategic partnerships, as single agent, or in combination with checkpoint inhibitors, other drugs or antigens. Its drug candidate KUP101 is the only TLR 4/7 agonist in development and consists of two small molecules, TLR4 agonist and TLR7 agonist, co-encapsulated. IND-enabling work is on-going for treatment of solid tumors and prophylaxis of infectious diseases. Kupando is a private company, seed financed by its CEO Johanna Holldack and based on technology invented by Dennis Carson’s Laboratory at the University of California San Diego. The Company’s management team brings a unique wealth of experience in business and drug development, gained in the US and Europe. Kupando is headquartered in Schoenefeld, Germany.

View Top Employees from Kupando GmbH

Website	https://www.kupando.com
Revenue	$2 million
Employees	10 (3 on RocketReach)
Founded	2018
Address	Willy-Brandt Platz 2, Schönefeld, Brandenburg 12529, DE
Phone	+49 30 5200586020
Industry	Biotechnology Research, Business Services General, Business Services
SIC	SIC Code 804 Companies, SIC Code 87 Companies, SIC Code 873 Companies, SIC Code 80 Companies
NAICS	NAICS Code 621 Companies, NAICS Code 62133 Companies, NAICS Code 6213 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 62 Companies